Ahead of World AIDS Day 2024, Professor Salim Abdool Karim and Dr Nikita Devnarain argue that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention alongside a well-functioning HIV treatment programme.
HIV prevention injections that can provide two, or even six, months of protection per shot have arguably been the biggest HIV story of the year. Ahead of World AIDS Day, Professor Francois Venter assesses the state of play and the critical next steps with these potentially game-changing new tools in the fight against HIV.
In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works. Elri Voigt goes over the new findings and unpacks the licenses that are expected to facilitate the availability of generic versions of the jab in over a hundred countries, including South Africa.
In South Africa, taking HIV treatment means taking one or more antiretroviral tablets a day. People in some other countries have the additional option of treatment in the form of two injections administered every two months. Elri Voigt unpacks why long-acting HIV treatment is not available in South Africa and asks why the push for HIV prevention jabs has been so much stronger than that for HIV treatment jabs.
Taking antiretrovirals to prevent HIV infection mostly still involves swallowing one or more pills a day. Some long-acting products that work for a month or two at a time have been approved but are not yet in wide use in South Africa. As delegates gathered for the 25th International AIDS Conference (AIDS 2024) last week, Elri Voigt takes stock of the latest developments in this fast-moving field.
An HIV prevention injection that provides six months of protection per shot has been shown to be highly effective in a pivotal trial largely conducted in South Africa. There are however some concerns as to when the injection will become available and how widely. Thabo Molelekwa and Marcus Low report.
